fda-expands-approval-of-gsk’s-respiratory-syncytial-virus-vaccine
FDA Expands Approval of GSK’s Respiratory Syncytial Virus Vaccine

FDA Expands Approval of GSK’s Respiratory Syncytial Virus Vaccine

By Zachary Stieber
1 Min Read

Adults as young as 18 can now receive the immunization.

FDA Expands Approval of GSK’s Respiratory Syncytial Virus Vaccine

The logo of the British multinational pharmaceutical company GlaxoSmithKline on top of its headquarters in London on Feb. 2, 2022. Justin Tallis/AFP via Getty Images

Zachary Stieber

|Updated:

U.S. regulators have expanded the approval for GlaxoSmithKline’s vaccine against respiratory syncytial virus (RSV), the company said March 13.

Adults as young as 18 can now receive the vaccine, provided they are at increased risk of lower respiratory tract disease caused by RSV because of having conditions such as chronic liver disease or compromised immune systems.

Cory Morgan: 5 New Major Projects Sound Promising, but Skepticism Won’t Fade Until Shovels Are in the Ground
Your Breath May Reveal Clues About Your Gut Health
British Man Who Lived in Vancouver Convicted in Overdose Deaths of US Servicemen
Salmonella Concerns Prompt Egg Sheet Recall in Two Provinces as Illnesses Reported
Trump Orders Federal Spectrum Shift to Secure US Lead in Global 6G Race
TAGGED:
Share This Article

You Might Also Like